Strides Pharma files BRSR for FY26, zero penalties reported

Strides Pharma filed its Business Responsibility and Sustainability Report for FY26 under SEBI LODR. 100% pharma manufacturer with 90.66 percent exports to 106 countries, no domestic sales. Standalone turnover Rs 21,801 crore, net worth Rs 28,953 crore. 2,810 permanent employees, 25 percent women on board. Zero regulatory fines, penalties or bribery cases. Holds ISO 14001, 45001, 50001 certifications and is committed to SBTi. Key material risks are product quality, human rights and geopolitics. Customer complaints rose to 426 from 368 year on year, with 58 pending.